bioRxiv Science⌕ Search

Biology subjects

Dev, H. S.

Publications and source records attributed to Dev, H. S..

2 recordsLinked to original sources

Translesion synthesis protein ImuA from Mycolicibacterium smegmatis is a hexameric helicase-nuclease

Translesion DNA synthesis (TLS) enables DNA replication across damaged DNA and promotes stress-induced mutagenesis that contributes to antibiotic resistance in bacteria. The conserved ImuABC mutasome is essential for TLS in many bacterial species, yet the molecular function of its accessory protein, ImuA, has remained elusive. Here we show that Mycolicibacterium smegmatis ImuA assembles into a hexameric complex, likely arranged as a dimer of trimers, with dual enzymatic activities that reshape current models of its role in DNA damage tolerance. We show that ImuA functions as an ATP-dependent helicase that preferentially unwinds DNA substrates containing single-stranded DNA overhangs and identify amino acids required for both hexamer formation and helicase activity. Unexpectedly, ImuA also possesses ATP-independent 5' exonuclease activity, selectively processing ssDNA substrates with free 5' ends. We show a basic patch on the N-terminus is essential for stabilizing both the nuclease motif and oligomerization. Together, these findings identify ImuA as an active DNA-processing enzyme rather than a passive accessory factor and establish oligomerization as a prerequisite for its function. Our work provides a mechanistic framework for understanding how ImuA may function within the ImuABC mutasome to coordinate DNA processing during translesion synthesis.

biochemistry↗

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

Recent phase 3 clinical trial readouts have shown benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) in metastatic, castration-resistant prostate cancer (mCRPC). While benefit was particularly evident in patients with tumours harbouring mutations in homologous recombination repair (HRR) genes, improved outcomes were also observed in patients with no such defined alterations in their cancers. Although there is literature linking AR activity with DNA repair pathways, the basis of the interaction between the AR and PARP is unclear. Here, we show that benefit of the combination of ARPi and PARPi in prostate cancer in vitro and in vivo models with no HRR mutations requires ARPi-responsive cells and a PARPi with PARP1-trapping activity, and does not involve an effect of PARPi treatment in modulating the transcriptional role of the AR. Combination benefit is driven by an increase in DNA damage in the form of DNA double-strand breaks and micronuclei formation, which is not due to a direct control of HRR gene transcription by the AR. In addition, we uncover a novel role of PARP1 in modulating AR recruitment to chromatin in the presence of DNA damage. These data shed new light on the interplay between PARP1 and the AR in dealing with genotoxic insults and provide a mechanism of action consistent with the observed clinical benefit of the combination of PARPi and ARPi in patients with prostate cancer. Statement of significanceCombination of androgen receptor pathway inhibitors and PARP inhibitors has shown efficacy in prostate cancer. We provide a mechanistic explanation through increased DNA damage accumulation observed in combination vs single-agent treatments.

cancer biology↗